EGETIS THERAPEUTICS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.1 SEK | +7.71% |
|
+20.54% | +45.16% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 60.73M 5.67M | Sales 2025 * | 514M 47.99M | Capitalization | 2.2B 205M |
|---|---|---|---|---|---|
| Net income 2024 * | -289M -26.96M | Net income 2025 * | 125M 11.66M | EV / Sales 2024 * | 33.5 x |
| Net cash position 2024 * | 167M 15.59M | Net cash position 2025 * | 226M 21.05M | EV / Sales 2025 * | 3.84 x |
| P/E ratio 2024 * |
-7.33
x | P/E ratio 2025 * |
13.9
x | Employees | 31 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Egetis Therapeutics AB
More press releases
| 1 day | +7.05% | ||
| 1 week | +19.79% | ||
| Current month | +26.18% | ||
| 1 month | +28.59% | ||
| 3 months | +31.32% | ||
| 6 months | +51.89% | ||
| Current year | +44.27% |
1 week
6.51
8.17
1 month
5.508.17
Current year
5.078.17
1 year
3.808.35
3 years
3.019.20
5 years
3.0121.00
10 years
3.0160.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
| Chief Tech/Sci/R&D Officer | - | 22-05-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 21-03-31 |
| Director/Board Member | 50 | 19-12-31 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 21-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 8.1 | +7.71% | 709 565 |
| 24-05-21 | 7.52 | +5.62% | 550,612 |
| 24-05-20 | 7.12 | +1.71% | 445,673 |
| 24-05-17 | 7 | +3.09% | 331,661 |
| 24-05-16 | 6.79 | +1.04% | 462,044 |
Delayed Quote Nasdaq Stockholm, May 22, 2024 at 10:44 am EDT
More quotes
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Companyâs pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
7.52
SEK
Average target price
14.3
SEK
Spread / Average Target
+90.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.27% | 206M | |
| +9.54% | 114B | |
| +13.14% | 107B | |
| -6.99% | 22.22B | |
| -1.51% | 21.28B | |
| -4.36% | 18.8B | |
| -6.02% | 17.51B | |
| -39.36% | 17.17B | |
| +6.28% | 14.14B | |
| +34.44% | 12.2B |
- Stock Market
- Equities
- EGTX Stock